|
|
 Previous Article | Table of Contents | Next Article 
Complex formation between urokinase and plasma protein C inhibitor in vitro
and in vivo
M Geiger, K Huber, J Wojta, L Stingl, F Espana, JH Griffin and BR Binder
Department of Medical Physiology, University of Vienna, Austria.
Protein C inhibitor (PCI) and plasminogen activator inhibitor 3 (PAI-3;
urinary urokinase inhibitor) are immunologically identical. The role of PCI
for urokinase (uPA) inhibition in vivo was investigated. We therefore
developed an enzyme-linked immunosorbent assay (ELISA) specific for uPA-PCI
complexes: Rabbit anti-PCI IgG was immobilized on a microtiter plate and
following incubation with uPA-PCI complex- containing samples, bound
uPA-PCI complexes were quantified with a horseradish-peroxidase-linked
monoclonal antibody (MoAb) to uPA. Using this assay, time, dose, and
heparin-dependent complexes were detected when uPA was incubated with
normal plasma or purified urinary PCI, whereas no complexes were measurable
using PCI-immunodepleted plasma. Plasma samples (containing 20 mmol/L
benzamidine to prevent complex formation ex vivo) from patients undergoing
systemic urokinase therapy (1 x 10(6) IU/60 min intravenously [IV]) after
myocardial infarction were also studied. uPA present in these plasma
samples (up to 1,200 ng/mL) had only 43% to 70% of the specific activity of
purified 2-chain uPA, suggesting that a major portion of uPA is complexed
to inhibitors. In these plasma samples uPA-PCI complexes were present in a
concentration corresponding to 21% to 25% of inactive uPA antigen. These
data suggest that at high uPA concentrations, such as during uPA therapy,
plasma PCI might contribute significantly to uPA inhibition in vivo.
Volume 74,
Issue 2,
pp. 722-728,
08/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. M. Malleier, O. Oskolkova, V. Bochkov, I. Jerabek, B. Sokolikova, T. Perkmann, J. Breuss, B. R. Binder, and M. Geiger
Regulation of protein C inhibitor (PCI) activity by specific oxidized and negatively charged phospholipids
Blood,
June 1, 2007;
109(11):
4769 - 4776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Gianotten, A. W.M. Schimmel, F. van der Veen, M.P. Lombardi, and J. C.M. Meijers
Absence of mutations in the PCI gene in subfertile men
Mol. Hum. Reprod.,
November 1, 2004;
10(11):
807 - 813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Prendes, E. Bielek, M. Zechmeister-Machhart, E. Vanyek-Zavadil, V. A. Carroll, J. Breuss, B. R. Binder, and M. Geiger
Synthesis and Ultrastructural Localization of Protein C Inhibitor in Human Platelets and Megakaryocytes
Blood,
August 15, 1999;
94(4):
1300 - 1312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. Pedersen, N. Brunner, G. Hoyer-Hansen, P. Hamer, D. Jarosz, B. Larsen, H. J. Nielsen, and R. W. Stephens
Determination of the Complex between Urokinase and Its Type-1 Inhibitor in Plasma from Healthy Donors and Breast Cancer Patients
Clin. Chem.,
August 1, 1999;
45(8):
1206 - 1213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G.L.M. Elisen, P. A.Kr. von dem Borne, B. N. Bouma, and J. C.M. Meijers
Protein C Inhibitor Acts as a Procoagulant by Inhibiting the Thrombomodulin-Induced Activation of Protein C in Human Plasma
Blood,
March 1, 1998;
91(5):
1542 - 1547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Carroll, M. R. Griffiths, M. Geiger, C. Merlo, M. Furlan, B. Lammle, and B. R. Binder
Plasma Protein C Inhibitor Is Elevated in Survivors of Myocardial Infarction
Arterioscler Thromb Vasc Biol,
January 1, 1997;
17(1):
114 - 118.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Manchanda and B. S. Schwartz
Interaction of Single-chain Urokinase and Plasminogen Activator Inhibitor Type 1
J. Biol. Chem.,
August 25, 1995;
270(34):
20032 - 20035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
